Status:
COMPLETED
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
Lead Sponsor:
Baxalta now part of Shire
Conditions:
Prothrombin Complex Factor Deficiency
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists in patients with ...
Eligibility Criteria
Inclusion
- Subject is at least 16 years or older at enrolment with acquired deficiency of prothrombin complex coagulation factors (II, VII, IX, X), due to oral anticoagulation with vitamin K antagonists (e.g. coumarin, warfarin), requiring reversal of oral anticoagulation for urgent surgery, or invasive procedure or acute bleeding episode
- Subject or parent/legally authorised representative has provided written informed consent
- Subject has INR \>= 2,0 at screening
- Subject is willing and able to comply with the requirements of the protocol
Exclusion
- Subject has laboratory and/or clinical symptoms which are clearly indicative of overt disseminated intravascular coagulation (DIC)
- Subject has been treated with whole blood, fresh frozen plasma (FFP), or platelets within 6 hours prior to study enrolment
- Subject has a hypersensitivity to prothrombin complex concentrate (PCC) constituents (including heparin-induced thrombocytopenia)
- Subject has blood loss of \>= 5 units of blood
- Subject has hereditary thrombophilia or bleeding disorder
- Subject has a life expectancy of \< 3 months
- Subject has been on oral anticoagulant treatment for a period of \< 4 weeks for the treatment of a thrombotic event such as deep vein thrombosis or pulmonary embolism
- Subject has an acute ischemic cardiovascular disorder
- Subject has or is suspected to have sepsis
- Subject with acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C)
- Subject has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrolment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Key Trial Info
Start Date :
July 9 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2012
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT01159210
Start Date
July 9 2010
End Date
April 7 2012
Last Update
May 5 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Landeskrankenhaus Feldkirch
Feldkirch, Austria, 6807
2
Universitätsklinik für Innere Medizin I (University Hospital for Internal Medicine I), Allgemeines Krankenhaus der Stadt Wien (General Hospital Vienna)
Vienna, Austria, 1090
3
Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel
Vienna, Austria, 1130
4
DEOEC, University of Debrecen, Medical and Health Science Centre
Debrecen, Hungary, 4032